Effects of the prolyl endopeptidase inhibitor S 17092 on cognitive deficits in Chronic low dose MPTP-treated monkeys

Neuropsychopharmacology

Volumn 26, Issue 2, 2002, Pages 176-182

  Schneider, J S ^a   Giardiniere, M ^a   Morain, P ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Cognition; Neuropeptide; Parkinsonism; Proline endopeptidase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; PROLYL ENDOPEPTIDASE INHIBITOR; S 17092; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; MACACA; MALE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; TASK PERFORMANCE; TREATMENT OUTCOME; VISUAL DISCRIMINATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; COGNITION DISORDERS; CONDITIONING, OPERANT; DISCRIMINATION LEARNING; DOPAMINE AGENTS; INDOLES; MACACA FASCICULARIS; MALE; PARKINSON DISEASE, SECONDARY; PATTERN RECOGNITION, VISUAL; PSYCHOMOTOR PERFORMANCE; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; THIAZOLES; THIAZOLIDINES;

EID: 0036146663     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(01)00307-4     Document Type: Article

References (25)

1. S 17092, a highly potent, specific and cell permeant inhibitor of human proline endopeptidase
2. Neuropeptide-degrading peptidase
3. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease
4. 'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa
5. Neuropeptides and Alzheimer's disease
6. The role of neuropeptides in learning: Focus on the neurokinin substance P
7. L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction
8. Cognitive deficits in the early stages of Parkinson's disease
9. Cognition enhancing effects of S 17092, a potent inhibitor of post-proline cleaving enzyme (PPCE)
10. S 17092, a new post-proline cleaving enzyme inhibitor: Memory enhancing effects and substance P neuromodulatory activity
11. Cognitive impairments associated with early Parkinson's disease
12. Decrease in substance P-like immunoreactivity in the substantia nigra and pallidum in Parkinsonian brains
13. Characterization of SIB-1508Y, the active enantiomer of a novel nicotinic acetylcholine receptor (NAChR) agonist, SIB-1765F
14. Planning and spatial working memory in Parkinson's disease
15. Visuo-spatial memory deficits at different stages of Parkinson's disease
16. Fronto-striatal cognitive deficits at different stages of Parkinson's disease
17. Dopamine (DA) and norepinephrine (NE) release in the prefrontal cortex (PFC) are regulated by different nAChR subtypes
18. Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys
19. Delayed matching-to-sample, object retrieval, and discrimination reversal deficits in chronic low dose MPTP-treated monkeys
20. Effects of the partial glycine agonist D-cycloserine on cognitive functioning in chronic low dose MPTP-treated monkeys
21. Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low dose MPTP-treated monkeys
22. Distractibility in early Parkinson's disease
23. Brain substance P receptors in Parkinson's disease
24. JTP-4819: A novel prolyl endopeptidase inhibitor with potential as a cognitive enhancer
25. Primate model of Parkinson's disease: Alterations in multiple opioid systems in the basal ganglia